Gene expression changes as markers of early lapatinib response in a panel of breast cancer cell lines

Molecular Cancer

Volumn 11, Issue , 2012, Pages

  O'Neill, Fiona ^a   Madden, Stephen F ^a   Aherne, Sinead T ^a   Clynes, Martin ^a   Crown, John ^a   Doolan, Padraig ^a   O'Connor, Robert ^a  

^a DUBLIN CITY UNIVERSITY   (Ireland)

Author keywords

Breast cancer; Co inertia analysis; Lapatinib response; Microarray

Indexed keywords

ALDEHYDE DEHYDROGENASE; AROMATIC HYDROCARBON RECEPTOR; CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 1BETA; INITIATION FACTOR 4E; LAPATINIB; MITOGEN ACTIVATED PROTEIN KINASE 9; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 2; NUCLEAR RECEPTOR SUB FAMILY 3 GROUP C MEMBER 1; OLFACTORY MARKER PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEASOME 26 S SUBUNIT NON ATPASE 13; PROTEIN; PROTEIN BID; RB1 INDUCIBLE COILED COIL PROTEIN 1; RETINOIC ACID RECEPTOR; RETINOID X RECEPTOR; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR E2A; TRANSCRIPTION FACTOR E2F3; TRANSCRIPTION FACTOR FKHRL1; TRANSCRIPTION FACTOR PAX3; TRANSCRIPTION FACTOR PAX9; TRANSCRIPTION FACTOR RUNX1; UNCLASSIFIED DRUG; ZINC FINGER PROTEIN 143;

ARTICLE; BINDING SITE; BREAST CANCER; CANCER CELL; CANCER RESISTANCE; COMPUTER MODEL; DOWN REGULATION; DRUG EXPOSURE; GENE CONTROL; GENE EXPRESSION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN MOTIF; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; TISSUE MICROARRAY; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; PROTEIN KINASE INHIBITORS; QUINAZOLINES; REPRODUCIBILITY OF RESULTS; TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84862242780     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-11-41     Document Type: Article

References (52)

1. Ferlay J, Shin H, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010, 127:2893-2917. 10.1002/ijc.25516, 21351269.
2. O'Brien NA, Browne BC, Chow L, Wang Y, Ginther C, Arboleda J, Duffy MJ, Crown J, O'Donovan N, Slamon DJ. Activated phosphoinositide 3-kinase/AKT signaling confers resistance to trastuzumab but not lapatinib. Mol Cancer Ther 2010, 9:1489-1502. 10.1158/1535-7163.MCT-09-1171, 20501798.
3. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987, 235:177-182. 10.1126/science.3798106, 3798106.
4. Ross JS, Fletcher JA. The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Stem Cells 1998, 16:413-428. 10.1002/stem.160413, 9831867.
5. Sawyers C. Targeted cancer therapy. Nature 2004, 432:294-297. 10.1038/nature03095, 15549090.
6. Paul MK, Mukhopadhyay AK. Tyrosine kinase - Role and significance in Cancer. Int J Med Sci 2004, 1:101-115. 1074718, 15912202.
7. Arora A, Scholar EM. Role of Tyrosine Kinase Inhibitors in Cancer Therapy. J Pharmacol Exp Ther 2005, 315:971-979. 10.1124/jpet.105.084145, 16002463.
8. Burris HA, Hurwitz HI, Dees EC, Dowlati A, Blackwell KL, O'Neil B, Marcom PK, Ellis MJ, Overmoyer B, Jones SF, Harris JL, Smith DA, Koch KM, Stead A, Mangum S, Spector NL. Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. J Clin Oncol 2005, 23:5305-5313. 10.1200/JCO.2005.16.584, 15955900.
9. Rusnak DW, Lackey K, Affleck K, Wood ER, Alligood KJ, Rhodes N, Keith BR, Murray DM, Knight WB, Mullin RJ, Gilmer TM. The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol Cancer Ther 2001, 1:85-94.
10. Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, Jagiello-Gruszfeld A, Crown J, Chan A, Kaufman B, Skarlos D, Campone M, Davidson N, Berger M, Oliva C, Rubin SD, Stein S, Cameron D. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006, 355:2733-2743. 10.1056/NEJMoa064320, 17192538.
11. Konecny GE, Pegram MD, Venkatesan N, Finn R, Yang G, Rahmeh M, Untch M, Rusnak DW, Spehar G, Mullin RJ, Keith BR, Gilmer TM, Berger M, Podratz KC, Slamon DJ. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res 2006, 66:1630-1639. 10.1158/0008-5472.CAN-05-1182, 16452222.
12. Gomez HL, Doval DC, Chavez MA, Ang PC, Aziz Z, Nag S, Ng C, Franco SX, Chow LWC, Arbushites MC, Casey MA, Berger MS, Stein SH, Sledge GW. Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer. J Clin Oncol 2008, 26:2999-3005. 10.1200/JCO.2007.14.0590, 18458039.
13. Blackwell KL, Burstein HJ, Storniolo AM, Rugo H, Sledge G, Koehler M, Ellis C, Casey M, Vukelja S, Bischoff J, Baselga J, O'Shaughnessy J. Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol 2010, 28:1124-1130. 10.1200/JCO.2008.21.4437, 20124187.
14. Jeffery IB, Madden SF, McGettigan PA, Perriere G, Culhane AC, Higgins DG. Integrating transcription factor binding site information with gene expression datasets. Bioinformatics 2007, 23:298-305. 10.1093/bioinformatics/btl597, 17127681.
15. Dolédec S, Chessel D. Co-inertia analysis: an alternative method for studying species - environment relationships. Freshw Biol 1994, 31:294-277.
16. Hegde PS, Rusnak D, Bertiaux M, Alligood K, Strum J, Gagnon R, Gilmer TM. Delineation of molecular mechanisms of sensitivity to lapatinib in breast cancer cell lines using global gene expression profiles. Mol Cancer Ther 2007, 6:1629-1640. 10.1158/1535-7163.MCT-05-0399, 17513611.
17. Dray S, Chessel D, Thioulouse J. Co-inertia analysis and the linking of ecological data tables. Ecology 2003, 84:3078-3089.
18. Madden S, Carpenter S, Jeffery I, Bjorkbacka H, Fitzgerald K, O'Neill L, Higgins D. Detecting microRNA activity from gene expression data. BMC Bioinforma 2010, 11:257.
19. Fagan A, Culhane AC, Higgins DG. A multivariate analysis approach to the integration of proteomic and gene expression data. Proteomics 2007, 7:2162-2171. 10.1002/pmic.200600898, 17549791.
20. Dolédec S, Chessel D. Rhythmes saisonniers et composantes stationelles en milieu aquatique I-Description d'un plan d'observations complet par projection de variables. Acta Oecologica Oecologica Generalis 1987, 8:403-426.
21. Culhane AC, Perrière G, Considine EC, Cotter TG, Higgins DG. Between-group analysis of microarray data. Bioinformatics 2002, 18:1600-1608. 10.1093/bioinformatics/18.12.1600, 12490444.
22. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U, Speed TP. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 2003, 4:249-264. 10.1093/biostatistics/4.2.249, 12925520.
23. Smyth GK. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 2004, 3:Article3.
24. Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. J Royal Statistical Soc Series B (Methodological) 1995, 57:289-300.
25. Culhane AC, Thioulouse J, Perrière G, Higgins DG. MADE4: an R package for multivariate analysis of gene expression data. Bioinformatics 2005, 21:2789-2790. 10.1093/bioinformatics/bti394, 15797915.
26. Breitling R, Armengaud P, Amtmann A, Herzyk P. Rank products: a simple, yet powerful, new method to detect differentially regulated genes in replicated microarray experiments. FEBS Lett 2004, 573:83-92. 10.1016/j.febslet.2004.07.055, 15327980.
27. Ho Sui SJ, Fulton DL, Arenillas DJ, Kwon AT, Wasserman WW. oPOSSUM: integrated tools for analysis of regulatory motif over-representation. Nucleic Acids Res 2007, 35:W245-W252. 10.1093/nar/gkm427, 1933229, 17576675.
28. Leonard MO, Howell K, Madden SF, Costello CM, Higgins DG, Taylor CT, McLoughlin P. Hypoxia selectively activates the CREB family of transcription factors in the in vivo lung. Am J Respir Crit Care Med 2008, 178:977-983. 10.1164/rccm.200712-1890OC, 2643223, 18689465.
29. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001, 25:402-408. 10.1006/meth.2001.1262, 11846609.
30. Rüegg J, Swedenborg E, Wahlström D, Escande A, Balaguer P, Pettersson K, Pongratz I. The transcription factor aryl hydrocarbon receptor nuclear translocator functions as an estrogen receptor beta-selective coactivator, and its recruitment to alternative pathways mediates antiestrogenic effects of dioxin. Mol Endocrinol 2008, 22:304-316.
31. Conde I, Paniagua R, Fraile B, Ruiz A, Arenas MI. Expression of vitamin D3 receptor and retinoid receptors in human breast cancer: identification of potential heterodimeric receptors. Int J Oncol 2004, 25:1183-1191.
32. Barhoover MA, Hall JM, Greenlee WF, Thomas RS. Aryl hydrocarbon receptor regulates cell cycle progression in human breast cancer cells via a functional interaction with cyclin-dependent kinase 4. Mol Pharmacol 2010, 77:195-201. 10.1124/mol.109.059675, 19917880.
33. Safe S, Krishnan V. Cellular and molecular biology of aryl hydrocarbon (Ah) receptor-mediated gene expression. Arch Toxicol Suppl 1995, 17:99-115. 10.1007/978-3-642-79451-3_8, 7786196.
34. Darro F, Cahen P, Vianna A, Decaestecker C, Nogaret JM, Leblond B, Chaboteaux C, Ramos C, Pétein M, Budel V, Schoofs A, Pourrias B, Kiss R. Growth inhibition of human in vitro and mouse in vitro and in vivo mammary tumor models by retinoids in comparison with tamoxifen and the RU-486 anti-progestagen. Breast Cancer Res Treat 1998, 51:39-55. 10.1023/A:1006098124087, 9877028.
35. Paroni G, Fratelli M, Gardini G, Bassano M, Flora JM, Zanetti A, Guarnaccia V, Ubezio P, Centritto F, Terao E, Garattini A. Synergistic antitumor activity of lapatinib and retinoids on a novel subtype of breast cancer with coamplification of ERBB2 and RARA. Oncogene 2011, doi:.
36. Wakasugi T, Izumi H, Uchiumi T, Suzuki H, Arao T, Nishio K, Kohno K. ZNF143 interacts with p73 and is involved in cisplatin resistance through the transcriptional regulation of DNA repair genes. Oncogene 2007, 26:5194-5203. 10.1038/sj.onc.1210326, 17297437.
37. Tan K, Shaw AL, Madsen B, Jensen K, Taylor-Papadimitriou J, Freemont PS. Human PLU-1 Has transcriptional repression properties and interacts with the developmental transcription factors BF-1 and PAX9. J Biol Chem 2003, 278:20507-20513. 10.1074/jbc.M301994200, 12657635.
38. Chano T, Ikebuchi K, Ochi Y, Tameno H, Tomita Y, Jin Y, Inaji H, Ishitobi M, Teramoto K, Nishimura I, Minami K, Inoue H, Isono T, Saitoh M, Shimada T, Hisa Y, Okabe H. RB1CC1 Activates RB1 Pathway and Inhibits Proliferation and Cologenic Survival in Human Cancer. PLoS One 2010, 5:e11404. 10.1371/journal.pone.0011404, 2894861, 20614030.
39. Melkoumian ZK, Peng X, Gan B, Wu X, Guan J. Mechanism of Cell Cycle Regulation by FIP200 in Human Breast Cancer Cells. Cancer Res 2005, 65:6676-6684. 10.1158/0008-5472.CAN-04-4142, 16061648.
40. Patel AS, Karagas MR, Spencer SK, Perry AE, Nelson HH. Gene-drug interaction at the glucocorticoid receptor increases risk of squamous cell skin cancer. AACR Meeting Abstracts 2006, 2006:1071.
41. Kim HH, Sierke SL, Koland JG. Epidermal growth factor-dependent association of phosphatidylinositol 3-kinase with the erbB3 gene product. J Biol Chem 1994, 269:24747-24755.
42. Paik J, Kollipara R, Chu G, Ji H, Xiao Y, Ding Z, Miao L, Tothova Z, Horner JW, Carrasco DR, Jiang S, Gilliland DG, Chin L, Wong WH, Castrillon DH, DePinho RA. FoxOs Are Lineage-Restricted Redundant Tumor Suppressors and Regulate Endothelial Cell Homeostasis. Cell 2007, 128:309-323. 10.1016/j.cell.2006.12.029, 1855089, 17254969.
43. D'Alessio A, De Luca A, Maiello MR, Lamura L, Rachiglio AM, Napolitano M, Gallo M, Normanno N. Effects of the combined blockade of EGFR and ErbB-2 on signal transduction and regulation of cell cycle regulatory proteins in breast cancer cells. Breast Cancer Res Treat 2010, 123:387-396. 10.1007/s10549-009-0649-x, 19946741.
44. LaBonte MJ, Wilson PM, Fazzone W, Russell J, Louie SG, El-Khoueiry A, Lenz H, Ladner RD. The Dual EGFR/HER2 Inhibitor Lapatinib Synergistically Enhances the Antitumor Activity of the Histone Deacetylase Inhibitor Panobinostat in Colorectal Cancer Models. Cancer Res 2011, 71:3635-3648. 10.1158/0008-5472.CAN-10-2430, 3118510, 21464044.
45. Lui VWY, Lau CPY, Ho K, Ng MHL, Cheng SH, Tsao S, Tsang CM, Lei KIK, Chan AT, Mok TSK. Anti-invasion, anti-proliferation and anoikis-sensitization activities of lapatinib in nasopharyngeal carcinoma cells. Invest New Drugs 2011, 29:1241-1252. 10.1007/s10637-010-9470-y, 20571878.
46. Schmidt M, Fernandez de Mattos S, van der Horst A, Klompmaker R, Kops GJPL, Lam EW, Burgering BMT, Medema RH. Cell Cycle Inhibition by FoxO Forkhead Transcription Factors Involves Downregulation of Cyclin D. Mol Cell Biol 2002, 22:7842-7852. 10.1128/MCB.22.22.7842-7852.2002, 134724, 12391153.
47. Zhang Y, Hamburger AW. Heregulin regulates the ability of the ErbB3-binding protein Ebp1 to bind E2F promoter elements and repress E2F-mediated transcription. J Biol Chem 2004, 279:26126-26133. 10.1074/jbc.M314305200, 15073182.
48. Ayroldi E, Zollo O, Bastianelli A, Marchetti C, Agostini M, Di Virgilio R, Riccardi C. GILZ mediates the antiproliferative activity of glucocorticoids by negative regulation of Ras signaling. J Clin Invest 2007, 117:1605-1615. 10.1172/JCI30724, 1865030, 17492054.
49. Takayama S, Rogatsky I, Schwarcz LE, Darimont BD. The glucocorticoid receptor represses cyclin D1 by targeting the Tcf-beta-catenin complex. J Biol Chem 2006, 281:17856-17863. 10.1074/jbc.M602290200, 16644723.
50. Chen Y, Dokmanovic M, Stein WD, Ardecky RJ, Roninson IB. Agonist and Antagonist of Retinoic Acid Receptors Cause Similar Changes in Gene Expression and Induce Senescence-like Growth Arrest in MCF-7 Breast Carcinoma Cells. Cancer Res 2006, 66:8749-8761. 10.1158/0008-5472.CAN-06-0581, 16951191.
51. Hu MC, Lee D, Xia W, Golfman LS, Ou-Yang F, Yang J, Zou Y, Bao S, Hanada N, Saso H, Kobayashi R, Hung M. IkappaB kinase promotes tumorigenesis through inhibition of forkhead FOXO3a. Cell 2004, 117:225-237. 10.1016/S0092-8674(04)00302-2, 15084260.
52. Liu B, Ordonez-Ercan D, Fan Z, Edgerton SM, Yang X, Thor AD. Downregulation of erbB3 abrogates erbB2-mediated tamoxifen resistance in breast cancer cells. Int J Cancer 2007, 120:1874-1882. 10.1002/ijc.22423, 17266042.